EN | RU
EN | RU

Help Support

Back

Study explores efficacy of optimized dual therapy for treatment-naive people infected wih H. pylori

Helicobacter pylori infection Helicobacter pylori infection
Helicobacter pylori infection Helicobacter pylori infection

What's new?

For the management of H. pylori-infected treatment-naive patients, two optimized dual regimens were found to have comparable compliance, effectiveness, and safety as the classical dual regimen.

In Helicobacter pylori (H. pylori)-infected individuals who had never received treatment before, two optimized amoxicillin (AMX) and proton pump inhibitors (PPI) dual regimens (Esomeprazole [ESO] 40 mg twice daily or 20 mg thrice daily with AMX 1 g thrice daily for 14 days) demonstrated identical effectiveness, safety, and compliance to the traditional dual regimen (ESO 20 mg + AMX 750 mg four times a day for 14 days). This randomized controlled trial examined the effectiveness, side effects, and patient compliance of three distinct high-dose dual regimens.

In this open-label, prospective, multicenter study, the qualified patients underwent high-dose dual therapy of various regimens with ESO and AMX. ESO 20 mg + AMX 750 mg was given four times a day to group A, ESO 40 mg twice a day  + AMX 1 g three times a day  was given to group B, and ESO 20 mg + AMX 1 g three times a day was given to group C at random. The three groups' H.pylori elimination rates, adverse events, and patient compliance were contrasted.

Notably, 945 of 1080 patients that were screened underwent randomization. Table 1 shows adverse event rates in the study groups. According to intention-to-treat (ITT), modified ITT, and per-protocol assessment, the H.pylori elimination rates in groups A, B, and C, are depicted in Table 1:

Antibiotic usage in the past two years lowered group B's elimination effect (ESO 40 mg twice a day, AMX 1 g three times a day). In group B, the adjusted intention-to-treat elimination rates were 81.4% vs. 90.0% for individuals who had or had not previously used antibiotics. The three groups' patient compliance levels were comparable.

Source:

Helicobacter

Article:

Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study

Authors:

Ying-Ying Han et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: